We close them.
Former FDA investigators, EMA auditors, and GxP architects — working line by line, finding by finding, until your 483 is a closed case.
Dr. Margaret Holloway
Senior Regulatory Strategist
"I spent two decades writing 483s. Now I make sure you never receive one unprepared."
Margaret led Pre-Approval Inspections at FDA's Office of Regulatory Affairs for 22 years, conducting more than 340 facility inspections across sterile injectables, biologics, and API manufacturing. She knows exactly which documentation gaps trigger a 483 observation — because she wrote them.
Today she coaches quality directors through the exact inspection she once led — walking through your SOPs, your batch records, your deviation logs with the same critical eye. The difference is that this time, she's on your side of the table.
"A well-prepared inspection response doesn't start the day the investigator walks in. It starts twelve months earlier — in your deviation system, your training records, your change control log."
With Dr. Holloway's inspection expertise, your team arrives ready — not reactive.
18 months of remediation. Collapsed to five.
A mid-size CDMO manufacturing sterile injectables received a Warning Letter with seven observations spanning aseptic technique, environmental monitoring, and out-of-specification investigation procedures. Eighteen months into their internal remediation, FDA had rejected two CAPA submissions and scheduled an establishment inspection.
We were engaged on a Monday. By Friday of week one, the full gap assessment was complete — observations rank-ordered by FDA risk weight, not internal comfort. The CAPA that followed didn't apologize for the past. It demonstrated mastery of the present.
"FDA doesn't want a longer response. They want evidence that the system that failed can no longer fail. That's a fundamentally different document."
Warning Letter received — 7 observations cited
Initial CAPA submitted, FDA requests additional data
Second CAPA cycle — process validation gaps identified
Establishment inspection scheduled, site not ready
Consent decree negotiations begin
Regulatory_Edge engaged — full gap assessment in week one
Prioritized CAPA with root cause evidence package
FDA response submitted — all 7 observations addressed
Establishment inspection passed. Warning Letter closed.
Facing a Warning Letter? Every week without a structured response is a week closer to an establishment inspection.
"An NDA filing isn't a document. It's an argument. And arguments have to be airtight."
Priya Nair spent fourteen years in regulatory affairs at two top-ten pharmaceutical companies before joining Regulatory_Edge. She has led 23 successful NDA filings — including three under accelerated approval pathways — and has navigated four Complete Response Letters back to approval without a single re-review cycle.
For biotech founders filing their first NDA, Priya functions as the regulatory function they don't yet have — building the submission strategy, managing the CMC narrative, and preparing the clinical team for advisory committee questions before FDA asks them. She has coached twelve first-time filers to approval.
"The biotech founders who struggle most aren't the ones with weak science. They're the ones who didn't start the regulatory conversation eighteen months before their planned filing date."
Filing your first NDA? Priya's team starts with strategy — not paperwork.
Priya Nair
NDA & Submissions Lead
Rewritten SOP + 100% operator requalification with media fill evidence
Full retrospective review + enhanced trending protocol implemented
New OOS SOP with FDA Phase II guidance alignment; 12-month lookback complete
Electronic batch record system implemented; 30-day parallel run data provided
Your Warning Letter response is only as strong as the evidence behind each CAPA. We build that evidence.
Four observations. Ninety days. Warning Letter closed.
A regional OSD manufacturer received a Warning Letter following a routine inspection that turned into a four-observation finding package. Their internal team had drafted responses that were technically accurate but strategically weak — acknowledging the observations without demonstrating systemic correction.
We rebuilt each CAPA from the root cause forward. Not just "what we did wrong," but"why the system allowed it" and "what makes recurrence structurally impossible." FDA reviewed the package and closed the Warning Letter without requesting additional information — a result that occurs in fewer than 30% of first-submission responses industry-wide.
"We don't write responses that satisfy the question. We write responses that close the file. There's a significant difference."
of Warning Letter responses are closed by FDA on first submission. Our clients close at 94%.
The inspection is coming.
The question is whether you're ready.
Whether you're staring down a 483, managing an active Warning Letter, or filing your first NDA with a team of twelve — a 60-minute strategy call with a Regulatory_Edge consultant will tell you exactly where you stand and what needs to happen next.
All consultations are confidential. Engagements governed by mutual NDA. Regulatory_Edge LLC is not affiliated with the U.S. Food & Drug Administration.